By Rajesh Patel, PhD
Investors in Ziopharm Oncology (NASDAQ:ZIOP) are eagerly awaiting the release of top-line data from the Phase III trial, PICASSO III, of Palifosfamide in first-line metastatic soft tissue sarcoma (STS). We believe that Threshold Pharmaceuticals (NASDAQ:THLD) represents an attractive derivative trade on ZIOP's data event, as outlined below.
In a previous article, we described the attractiveness of derivative trades on biotech binary events. Briefly, a derivative is a security whose value is directly or indirectly linked to another, the primary equity. In our case, we'll be utilizing the stock of a related company for risk-adjusted involvement in the upcoming binary event of a similar company. These related companies often see similar reactions in their stock price on a positive outcome for the primary company, with a less significant downside move on a negative outcome.
Take, for example, Orexigen's (NASDAQ:OREX) rally in the middle of last year in tandem with the approval of Arena's (NASDAQ:ARNA) weight-loss drug Belviq. Despite having 18 months to go before its own obesity treatment, Contrave, might receive FDA approval, shares of Orexigen climbed 25% in sentiment to Arena's approval. A note of caution on the THLD/ZIOP derivative: Unlike OREX, THLD does not have a history of trading in parallel to ZIOP.
Now, Ziopharm's lead candidate Palifosfamide (PALI) is isophosphoramide mustard (IPM). As seen in the figure below, Threshold's lead drug candidate, TH-302, is a prodrug of PALI. Once metabolized in the body, its active molecule (circled below) is highly similar to PALI, except PALI's chlorine atoms have been replaced by bromine.
Click to enlarge images.
According to Threshold, under the hypoxic conditions within the margins of tumors, the ring on the left-hand side of the TH-302 molecule is removed, yielding Bromo-Isophosphoramide mustard (BR-IPM). It's believed that under normal oxygen levels (normoxic conditions) the electron exchange reaction that separates the ring from the Br-IPM is offset by the reverse reaction, the combination of Br-IPM with oxygen to produce the prodrug again. For an overview of hypoxia-activated prodrugs see this presentation from ASCO 2007. Given that PALI and TH-302 have very similar active components, and given that both of these compounds are derivatives of the anti-cancer drug Ifosfamide, it is reasonable to expect that TH-302 may have similar cancer fighting capabilities to PALI.
TH-302 is undergoing a Phase III trial in combination with doxorubicin in STS. Unlike ZIOP, Threshold obtained a special protocol assessment (SPA) for their trial -- read more about SPAs here. The company has a collaboration with Merck, and due to milestones under this partnership, the company has over $100 million in cash on hand.
In a separate article, we laid out the bull and bear cases for Palifosfamide as well as a risk-weighted fair value calculation for the stock ahead of the data. Our analysis indicates that on a risk-weighted basis, ZIOP's fair value ahead of the data event is $6.17 based on a 60% probability of trial success. If PALI fails to show a significant progression free survival benefit, we see ZIOP's downside to below $1.50, and on positive data, we see upside in the range of $8-$10.
Meanwhile, and as the chart below shows, THLD has been trading in a channel since November. The stock began a downward slide after announcing updated data from a Phase II trial of TH-302 in pancreatic cancer that showed that, while TH-302 plus gemcitabine resulted in a progression free survival (PFS) benefit, the overall survival (OS) benefit in the trial was not statistically significant.
We believe that THLD potentially benefits no matter which way Ziopharm's Palifosfamide data turn out. If the data are positive, the inference is that since TH-302 is a prodrug of PALI, TH-302's STS trial should also work. On the other hand, if ZIOP's trial fails, the differentiated nature of TH-302 (activated in hypoxic regions of the tumors) means that there is still reason to believe TH-302 could work. And with Palifosfamide out of the running, TH-302's addressable market increases significantly.
THLD is currently supported by the 20-day and 50-day exponential moving averages (EMAs), which stand at $4.76 and $4.86, respectively. The 200-day EMA creates overhead resistance at $5.12. Should ZIOP announce positive data, we expect that THLD should break above the overhead resistance and may begin to establish a new base at a higher level.
THLD's trial in STS is ongoing, with final data collection by the summer of 2014. When Threshold announced their partnership with Merck in February 2012, the stock climbed from the $2 range to the $9 range, a 350% increase. Last September, when the company reported the lack of a statistically significant OS benefit in the Phase II pancreatic cancer trial, THLD retraced by 50%, taking the stock down to a more attractive valuation. Given the impending catalyst for ZIOP, the similarity of PALI and TH-302, and the fact that THLD is well-capitalized and has a global development partner that is funding the majority of TH-302's development, we see a long position in TLHD as an attractive and risk-mitigated way to trade the palifosfamide Phase III data event, due the last week of March.
Disclosure: I am long THLD. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.
Additional disclosure: PropThink is a team of editors, analysts, and writers. This article was written by Rajesh Patel, Ph.D. We did not receive compensation for this article, and we have no business relationship with any company whose stock is mentioned in this article. Use of PropThink’s research is at your own risk. You should do your own research and due diligence before making any investment decision with respect to securities covered herein.You should assume that as of the publication date of any report or letter, PropThink, LLC and persons or entities with whom it has relation ships (collectively referred to as "PropThink") has a position in all stocks (and/or options of the stock) covered herein that is consistent with the position set forth in our research report. Following publication of any report or letter, PropThink intends to continue transacting in the securities covered herein, and we may be long, short, or neutral at any time hereafter regardless of our initial recommendation. To the best of our knowledge and belief, all information contained herein is accurate and reliable, and has been obtained from public sources we believe to be accurate and reliable, and not from company insiders or persons who have a relationship with company insiders. Our full disclaimer is available at www.propthink.com/disclaimer.